Cogent Biosciences: Fairmount Share Sale Boosts Market Access & Growth Prospects
Cogent Biosciences: Fairmount’s 3.5 M-share sale highlights strategic rebalancing, while the firm’s Bezuclastinib pipeline and market‑access plan signal high‑growth biotech potential.
3 minutes to read